JP2012509889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509889A5 JP2012509889A5 JP2011537663A JP2011537663A JP2012509889A5 JP 2012509889 A5 JP2012509889 A5 JP 2012509889A5 JP 2011537663 A JP2011537663 A JP 2011537663A JP 2011537663 A JP2011537663 A JP 2011537663A JP 2012509889 A5 JP2012509889 A5 JP 2012509889A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- vegf antibody
- cyclophosphamide
- subject
- m2iv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11710208P | 2008-11-22 | 2008-11-22 | |
| US61/117,102 | 2008-11-22 | ||
| US17800909P | 2009-05-13 | 2009-05-13 | |
| US61/178,009 | 2009-05-13 | ||
| US17930709P | 2009-05-18 | 2009-05-18 | |
| US61/179,307 | 2009-05-18 | ||
| PCT/US2009/065381 WO2010059969A2 (en) | 2008-11-22 | 2009-11-20 | Anti-angiogenesis therapy for the treatment of breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016163087A Division JP6850562B2 (ja) | 2008-11-22 | 2016-08-23 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509889A JP2012509889A (ja) | 2012-04-26 |
| JP2012509889A5 true JP2012509889A5 (enExample) | 2013-01-24 |
| JP6041489B2 JP6041489B2 (ja) | 2016-12-07 |
Family
ID=42154236
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537663A Active JP6041489B2 (ja) | 2008-11-22 | 2009-11-20 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2016163087A Active JP6850562B2 (ja) | 2008-11-22 | 2016-08-23 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2018080848A Withdrawn JP2018138583A (ja) | 2008-11-22 | 2018-04-19 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2020076277A Pending JP2020128389A (ja) | 2008-11-22 | 2020-04-22 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016163087A Active JP6850562B2 (ja) | 2008-11-22 | 2016-08-23 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2018080848A Withdrawn JP2018138583A (ja) | 2008-11-22 | 2018-04-19 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
| JP2020076277A Pending JP2020128389A (ja) | 2008-11-22 | 2020-04-22 | 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20100143351A1 (enExample) |
| EP (3) | EP2361085B9 (enExample) |
| JP (4) | JP6041489B2 (enExample) |
| KR (3) | KR20170015525A (enExample) |
| CN (2) | CN102223897B (enExample) |
| AR (1) | AR074203A1 (enExample) |
| AU (1) | AU2009316409A1 (enExample) |
| BR (1) | BRPI0916138A2 (enExample) |
| CA (1) | CA2744158A1 (enExample) |
| CL (1) | CL2011001186A1 (enExample) |
| CY (1) | CY1118549T1 (enExample) |
| DK (2) | DK2752189T3 (enExample) |
| ES (2) | ES2535404T5 (enExample) |
| HR (1) | HRP20170059T1 (enExample) |
| HU (2) | HUE032693T2 (enExample) |
| IL (2) | IL212998A (enExample) |
| LT (1) | LT2752189T (enExample) |
| MX (2) | MX340724B (enExample) |
| PH (1) | PH12014502507A1 (enExample) |
| PL (2) | PL2752189T3 (enExample) |
| PT (1) | PT2752189T (enExample) |
| RU (1) | RU2531948C2 (enExample) |
| SG (1) | SG171780A1 (enExample) |
| SI (2) | SI2752189T1 (enExample) |
| SM (1) | SMT201700173T1 (enExample) |
| TW (2) | TWI612971B (enExample) |
| WO (1) | WO2010059969A2 (enExample) |
| ZA (1) | ZA201103321B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2927556T3 (es) | 2008-05-15 | 2022-11-08 | Celgene Corp | Formulaciones orales de análogos de citidina y métodos de uso de los mismos |
| PL2752189T3 (pl) * | 2008-11-22 | 2017-04-28 | F. Hoffmann-La Roche Ag | Zastosowanie przeciwciała anty-VEGF w połączeniu z chemioterapią do leczenia raka sutka |
| MA34059B1 (fr) | 2010-02-23 | 2013-03-05 | Genentech Inc | Thérapie anti-angiogénique pour le traitement du cancer des ovaires |
| PL4234033T3 (pl) * | 2011-10-14 | 2025-04-28 | F. Hoffmann-La Roche Ag | Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2 |
| JP6162709B2 (ja) | 2011-11-01 | 2017-07-12 | セルジーン コーポレイション | シチジンアナログの経口製剤を使用して癌を治療する方法 |
| EP3553083A1 (en) | 2012-03-13 | 2019-10-16 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of ovarian cancer |
| FI3626270T3 (fi) | 2013-08-26 | 2024-01-11 | Novartis Ag | Sydän- ja verisuonitautien hoito |
| US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CA2950936A1 (en) * | 2014-07-03 | 2016-01-07 | Imclone Llc | Combination therapy of olaratumab, cardioprotective agent and doxorubicin for the treatment of soft tissue sarcoma |
| EP3632478B1 (en) | 2014-07-14 | 2022-09-28 | University of Utah Research Foundation | In situ solidifying solution and methods of making and using thereof |
| CN104991065B (zh) * | 2015-07-07 | 2017-01-11 | 复旦大学附属金山医院 | 一种用于诊断乳腺癌的三联标志物及其应用 |
| CA2998469C (en) | 2015-09-14 | 2025-12-09 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| WO2019084548A1 (en) * | 2017-10-27 | 2019-05-02 | University Of Utah Research Foundation | COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS |
| AU2019212513B2 (en) | 2018-01-26 | 2024-10-31 | Fluidx Medical Technology, Llc | Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| JP2021517135A (ja) * | 2018-03-09 | 2021-07-15 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 化学療法抵抗性がんの組合せ処置 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN111710425A (zh) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 |
| IL322165A (en) * | 2023-01-19 | 2025-09-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anti-HER2 antibody-drug conjugate for breast cancer treatment |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| DK1238986T3 (da) | 1992-10-28 | 2008-09-29 | Genentech Inc | Anvendelse af antagonister mod vaskulær endotelcellevækstfaktor |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| PT2275119E (pt) | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DE69836729T2 (de) | 1997-04-07 | 2007-12-13 | Genentech, Inc., South San Francisco | Anti-vefg antibodies |
| TR199902818T2 (xx) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| DE60030323T2 (de) | 1999-12-24 | 2007-10-11 | Genentech, Inc., South San Francisco | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
| WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1629010A1 (en) | 2003-05-30 | 2006-03-01 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| MX2007000610A (es) | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina. |
| KR101254815B1 (ko) | 2004-07-20 | 2013-09-03 | 제넨테크, 인크. | 안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도 |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR20140148491A (ko) * | 2006-12-19 | 2014-12-31 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제 |
| EP2125016A2 (en) * | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
| PL2752189T3 (pl) | 2008-11-22 | 2017-04-28 | F. Hoffmann-La Roche Ag | Zastosowanie przeciwciała anty-VEGF w połączeniu z chemioterapią do leczenia raka sutka |
| CN113168667B (zh) | 2019-02-27 | 2024-05-14 | 谷歌有限责任公司 | 灰度直方图生成 |
-
2009
- 2009-11-20 PL PL13189711T patent/PL2752189T3/pl unknown
- 2009-11-20 AR ARP090104477A patent/AR074203A1/es unknown
- 2009-11-20 HU HUE13189711A patent/HUE032693T2/en unknown
- 2009-11-20 DK DK13189711.8T patent/DK2752189T3/en active
- 2009-11-20 ES ES09764134.4T patent/ES2535404T5/es active Active
- 2009-11-20 KR KR1020177002172A patent/KR20170015525A/ko not_active Ceased
- 2009-11-20 AU AU2009316409A patent/AU2009316409A1/en not_active Abandoned
- 2009-11-20 HU HUE09764134A patent/HUE024872T2/en unknown
- 2009-11-20 JP JP2011537663A patent/JP6041489B2/ja active Active
- 2009-11-20 LT LTEP13189711.8T patent/LT2752189T/lt unknown
- 2009-11-20 RU RU2011125518/15A patent/RU2531948C2/ru active
- 2009-11-20 SM SM20170173T patent/SMT201700173T1/it unknown
- 2009-11-20 DK DK09764134.4T patent/DK2361085T4/en active
- 2009-11-20 MX MX2014002003A patent/MX340724B/es unknown
- 2009-11-20 SI SI200931591T patent/SI2752189T1/sl unknown
- 2009-11-20 SI SI200931187T patent/SI2361085T2/sl unknown
- 2009-11-20 CN CN200980146589.3A patent/CN102223897B/zh not_active Expired - Fee Related
- 2009-11-20 WO PCT/US2009/065381 patent/WO2010059969A2/en not_active Ceased
- 2009-11-20 EP EP09764134.4A patent/EP2361085B9/en not_active Not-in-force
- 2009-11-20 MX MX2011005383A patent/MX2011005383A/es active IP Right Grant
- 2009-11-20 CA CA2744158A patent/CA2744158A1/en not_active Abandoned
- 2009-11-20 PT PT131897118T patent/PT2752189T/pt unknown
- 2009-11-20 ES ES13189711.8T patent/ES2611337T3/es active Active
- 2009-11-20 BR BRPI0916138A patent/BRPI0916138A2/pt not_active Application Discontinuation
- 2009-11-20 TW TW104125142A patent/TWI612971B/zh not_active IP Right Cessation
- 2009-11-20 PL PL09764134T patent/PL2361085T5/pl unknown
- 2009-11-20 US US12/623,297 patent/US20100143351A1/en not_active Abandoned
- 2009-11-20 TW TW098139537A patent/TWI542359B/zh not_active IP Right Cessation
- 2009-11-20 KR KR1020187030405A patent/KR20180117734A/ko not_active Ceased
- 2009-11-20 CN CN201510520134.0A patent/CN105214086B/zh not_active Expired - Fee Related
- 2009-11-20 KR KR1020117014272A patent/KR101807319B1/ko not_active Expired - Fee Related
- 2009-11-20 EP EP16188246.9A patent/EP3178478A1/en not_active Withdrawn
- 2009-11-20 SG SG2011036696A patent/SG171780A1/en unknown
- 2009-11-20 EP EP13189711.8A patent/EP2752189B1/en not_active Revoked
-
2011
- 2011-05-06 ZA ZA2011/03321A patent/ZA201103321B/en unknown
- 2011-05-19 IL IL212998A patent/IL212998A/en active IP Right Grant
- 2011-05-20 CL CL2011001186A patent/CL2011001186A1/es unknown
-
2014
- 2014-11-10 PH PH12014502507A patent/PH12014502507A1/en unknown
-
2015
- 2015-05-15 US US14/714,177 patent/US20150246124A1/en not_active Abandoned
-
2016
- 2016-01-21 IL IL243741A patent/IL243741A0/en unknown
- 2016-05-13 US US15/154,797 patent/US20160243227A1/en not_active Abandoned
- 2016-08-23 JP JP2016163087A patent/JP6850562B2/ja active Active
- 2016-12-20 US US15/385,602 patent/US20170100478A1/en not_active Abandoned
-
2017
- 2017-01-16 HR HRP20170059TT patent/HRP20170059T1/hr unknown
- 2017-01-25 CY CY20171100116T patent/CY1118549T1/el unknown
-
2018
- 2018-04-19 JP JP2018080848A patent/JP2018138583A/ja not_active Withdrawn
-
2020
- 2020-04-22 JP JP2020076277A patent/JP2020128389A/ja active Pending
- 2020-05-15 US US16/874,936 patent/US20210093715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509889A5 (enExample) | ||
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2013520442A5 (enExample) | ||
| RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
| JP2025020147A5 (enExample) | ||
| JP2017031160A5 (enExample) | ||
| Heinemann | Gemcitabine plus cisplatin for the treatment of metastatic breast cancer | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| JP2013173775A5 (enExample) | ||
| JP2008503476A5 (enExample) | ||
| JP2012506448A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| RU2011147051A (ru) | Адъювантная терапия рака | |
| JP2018522851A5 (enExample) | ||
| JP2019526595A5 (enExample) | ||
| JP2012522837A5 (enExample) | ||
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| Kim et al. | A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| JP2013501801A5 (enExample) | ||
| JP2010525042A5 (enExample) | ||
| RU2012109932A (ru) | Антиангиогенная терапия для лечения ранее подвергавшегося лечению рака молочной железы | |
| JPWO2020160527A5 (enExample) | ||
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer |